The debate on whether to shorten adjuvant chemotherapy for colon cancer from six to three months takes centre stage today in a special session at the ESMO 2017 Congress in Madrid.
Sep 11, 2017
Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage II lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress ...
Sep 11, 2017
Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to ...
Sep 11, 2017
An analysis of more than 100 clinical trials found that they were often unregistered, unpublished and had discrepancies in the reporting of primary outcomes, according to a study published by JAMA. The study is being released ...
Sep 11, 2017
